Abstract
Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Current Signal Transduction Therapy
Title:NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation
Volume: 10 Issue: 1
Author(s): Chun Huang, Shan-mao Nie, Yi-ming Liu, Min Li, Jian-ping Gong and Meng-hao Wang
Affiliation:
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Abstract: Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Export Options
About this article
Cite this article as:
Huang Chun, Nie Shan-mao, Liu Yi-ming, Li Min, Gong Jian-ping and Wang Meng-hao, NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1573407211666150603201802
DOI https://dx.doi.org/10.2174/1573407211666150603201802 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry The Importance of Strict Blood Glucose Control with Insulin Therapy in the Intensive Care Unit
Current Diabetes Reviews The Coronary Collateral Circulation in Man
Current Cardiology Reviews Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy Technetium-99m Cysteine; A Novel Radiopharmaceutical for Detection of Experimental Myocardial Infarction in Rats
Current Radiopharmaceuticals Subject Index to Volume 1
Current Neurovascular Research From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers&#
Current Vascular Pharmacology Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Necroptosis: Who Knew There were so Many Interesting Ways to Die?
CNS & Neurological Disorders - Drug Targets Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets